Panacea Acquisition Stock Quote NUVB - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.79

Bid

Ask

Volume

1,238,660

3.64 Day's Range 3.83

0.95 52 Week Range 4.1598

Market Cap

936.777M

Previous Close

3.69

Open

3.75

Last Trade

3.83

Last Trade Time

19:13:29

Financial Volume

$ 4,606,606

VWAP

3.719

Average Volume (3m)

1,643,447

Shares Outstanding

247,170,648

Dividend Yield

PE Ratio

-12.16

Earnings Per Share (EPS)

-0.31

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was $3.69. Over the last year, Panacea Acquisition shares have traded in a share price range of $ 0.95 to $ 4.1598.

Panacea Acquisition currently has 247,170,648 shares outstanding. The market capitalization of Panacea Acquisition is $912.06 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -12.16.

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Company to present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncology (ESMO) Congress 2024, which will support Nuvation Bio’s New Drug...

Form PRER14A - Preliminary Proxy Soliciting materials

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.62	19.5583596215	3.17	3.83	2.985	1535369	3.35244975	CS
4	0.71	23.0519480519	3.08	3.83	2.87	2070810	3.16856853	CS
12	0.41	12.1301775148	3.38	3.83	2.57	1643447	3.10562948	CS
26	2.08	121.637426901	1.71	4.1598	1.52	1473116	2.95828226	CS
52	1.97	108.241758242	1.82	4.1598	0.95	1244988	2.28069069	CS
156	-4.8	-55.8789289872	8.59	10.45	0.95	940873	3.63419217	CS
260	-6.21	-62.1	10	15.23	0.95	935708	4.62841325	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CGTXCognition Therapeutics Inc	$ 3.47 (46.41%)	4.6M
NAMSNewAmsterdam Pharma Company NV	$ 22.49 (19.25%)	18.82k
RNAZTransCode Therapeutics Inc	$ 0.341 (15.36%)	6.61M
YYGHYY Group Holding Ltd	$ 0.84 (14.60%)	743
YIBOPlanet Image International Ltd	$ 3.32 (13.89%)	56.73k
VTVTvTv Therapeutics Inc	$ 13.00 (-38.68%)	33.14k
CEROCERo Therapeutics Holdings Inc	$ 0.1669 (-34.80%)	3.51M
TGLTreasure Global Inc	$ 1.32 (-28.65%)	53.49k
LUXHLuxUrban Hotels Inc	$ 0.1587 (-16.91%)	1.31M
RGCRegencell Bioscience Holdings Ltd	$ 10.69 (-13.02%)	14.55k
SLNASelina Hospitality PLC	$ 0.0281 (-6.33%)	23.11M
RNAZTransCode Therapeutics Inc	$ 0.341 (15.36%)	6.61M
CGTXCognition Therapeutics Inc	$ 3.47 (46.41%)	4.6M
TLTiShares 20 plus Year Treasury Bond	$ 92.94 (-0.05%)	3.9M
CEROCERo Therapeutics Holdings Inc	$ 0.1669 (-34.80%)	3.51M